Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue

Translational Psychiatry

Volumn 6, Issue 1, 2016, Pages

  Lai, C Y ^a,b   Lee, S Y ^a   Scarr, E ^b,c   Yu, Y H ^a   Lin, Y T ^d   Liu, C M ^d   Hwang, T J ^d   Hsieh, M H ^d   Liu, C C ^d   Chien, Y L ^d   Udawela, M ^b   Gibbons, A S ^b,c   Everall, I P ^b,c   Hwu, H G ^d   Dean, B ^b,c   Chen, W J ^a,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ACUTE DISEASE; ADULT; AGED; BLOOD; BRAIN; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; SCHIZOPHRENIA; YOUNG ADULT;

ACUTE DISEASE; ADULT; AGED; BIOMARKERS; BRAIN; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; SCHIZOPHRENIA; YOUNG ADULT;

EID: 85017128569     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2015.213     Document Type: Article

References (48)

1. van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203–212.
2. Qureshi IA, Mehler MF. Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease. Nat Rev Neurosci 2012; 13: 528–541.
3. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8: 355–367.
4. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 261–268.
5. Seo MS, Scarr E, Lai CY, Dean B. Potential molecular and cellular mechanism of psychotropic drugs. Clin Psychopharmacol Neurosci 2014; 12: 94–110.
6. Liu S, Yuan YB, Guan LL, Wei H, Cheng Z, Han X et al. MiRNA-365 and miRNA-520c-3p respond to risperidone treatment in first-episode schizophrenia after a 1 year remission. Chin Med J (Engl) 2013; 126: 2676–2680.
7. Song HT, Sun XY, Zhang L, Zhao L, Guo ZM, Fan HM et al. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after anti-psychotic treatment. J Psychiatr Res 2014; 54: 134–140.
8. Gardiner E, Carroll A, Tooney PA, Cairns MJ. Antipsychotic drug-associated gene-miRNA interaction in T-lymphocytes. Int J Neuropsychopharmacol 2014; 17: 929–943.
9. Dean B, Keriakous D, Scarr E, Thomas EA. Gene expression profiling in Brodmann's area 46 from subjects with schizophrenia. Aust NZ J Psychiatry 2007; 41: 308–320.
10. Narayan S, Tang B, Head SR, Gilmartin TJ, Sutcliffe JG, Dean B et al. Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res 2008; 1239: 235–248.
11. Dean B, Gibbons A, Scarr E, Thomas EA. Changes in gene expression in subjects with schizophrenia associated with disease progression. In: Handbook of Schizophrenia Spectrum Disorders, vol. 1. Springer Netherlands: Dordrecht, The Netherlands, 2011; pp 237–251.
12. Rao P, Benito E, Fischer A. MicroRNAs as biomarkers for CNS disease. Front Mol Neurosci 2013; 6: 39.
13. Maffioletti E, Tardito D, Gennarelli M, Bocchio-Chiavetto L. Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Front Cell Neurosci 2014; 8: 75.
14. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233.
15. Sun W, Julie Li YS, Huang HD, Shyy JY, Chien S. microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Biomed Eng 2010; 12: 1–27.
16. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and con-siderations. Nat Rev Genet 2012; 13: 358–369.
17. Lai CY, Yu SL, Hsieh MH, Chen CH, Chen HY, Wen CC et al. MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One 2011; 6: e21635.
18. Gardiner E, Beveridge NJ, Wu JQ, Carr V, Scott RJ, Tooney PA et al. Imprinted DLK1-DIO3 region of 14q32 defines a schizophrenia-associated miRNA signature in peripheral blood mononuclear cells. Mol Psychiatry 2012; 17: 827–840.
19. Santarelli DM, Liu B, Duncan CE, Beveridge NJ, Tooney PA, Schofield PR et al. Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine. Psychopharmacology 2013; 227: 67–78.
20. Miller BH, Zeier Z, Xi L, Lanz TA, Deng S, Strathmann J et al. MicroRNA-132 dysregulation in schizophrenia has implications for both neurodevelopment and adult brain function. Proc Natl Acad Sci USA 2012; 109: 3125–3130.
21. Kim AH, Reimers M, Maher B, Williamson V, McMichael O, McClay JL et al. MicroRNA expression profiling in the prefrontal cortex of individuals affected with schizophrenia and bipolar disorders. Schizophr Res 2010; 124: 183–191.
22. Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ. Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol Psychiatry 2011; 69: 180–187.
23. Moreau MP, Bruse SE, Jornsten R, Liu YS, Brzustowicz LM. Chronological changes in MicroRNA expression in the developing human brain. PLoS One 2013; 8: e60480.
24. Redshaw N, Wheeler G, Hajihosseini MK, Dalmay T. microRNA-449 is a putative regulator of choroid plexus development and function. Brain Res 2009; 1250: 20–26.
25. Chen H, Sun JG, Cao XW, Ma XG, Xu JP, Luo FK et al. Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559. Biochem Biophys Res Commun 2009; 385: 596–600.
26. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008; 9: 437–452.
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. APA: Washington, DC, USA, 1994.
28. Kay SR. Positive and Negative Syndromes in Schizophrenia: Assessment and Research. Brunner/Mazel: New York, NY, USA, 1991.
29. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255–262.
30. Hill C, Keks N, Roberts S, Opeskin K, Dean B, MacKinnon A et al. Problem of diagnosis in postmortem brain studies of schizophrenia. Am J Psychiatry 1996; 153: 533–537.
31. Remington G. Antipsychotics (neuroleptics). In: Clinical Handbook of Psychotropic Drugs, vol. 9. Hogrefe & Huber Publishers: Seattle, WA, USA, 1999, pp 55–84.
32. Udawela M, Scarr E, Hannan AJ, Thomas EA, Dean B. Phospholipase C beta 1 expression in the dorsolateral prefrontal cortex from patients with schizophrenia at different stages of illness. Aust NZ J Psychiatry 2011; 45: 140–147.
33. Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS et al. Real-time PCR quantification of precursor and mature microRNA. Methods 2008; 44: 31–38.
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 CT method. Methods 2001; 25: 402–408.
35. Lai CY, Wu YT, Yu SL, Yu YH, Lee SY, Liu CM et al. Modulated expression of human peripheral blood microRNAs from infancy to adulthood and its role in aging. Aging Cell 2014; 13: 679–689.
36. Ibanez-Ventoso C, Yang M, Guo S, Robins H, Padgett RW, Driscoll M. Modulated microRNA expression during adult lifespan in Caenorhabditis elegans. Aging Cell 2006; 5: 235–246.
37. de Lencastre A, Pincus Z, Zhou K, Kato M, Lee SS, Slack FJ. MicroRNAs both promote and antagonize longevity in C-elegans. Curr Biol 2010; 20: 2159–2168.
38. Somel M, Guo S, Fu N, Yan Z, Hu HY, Xu Y et al. MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res 2010; 20: 1207–1218.
39. Liu N, Landreh M, Cao K, Abe M, Hendriks GJ, Kennerdell JR et al. The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila. Nature 2012; 482: 519–523.
40. Beveridge NJ, Santarelli DM, Wang X, Tooney PA, Webster MJ, Weickert CS et al. Maturation of the human dorsolateral prefrontal cortex coincides with a dynamic shift in microRNA expression. Schizophr Bull 2014; 40: 399–409.
41. Insel TR. Rethinking schizophrenia. Nature 2010; 468: 187–193.
42. Jeste DV, Wolkowitz OM, Palmer BW. Divergent trajectories of physical, cognitive, and psychosocial aging in schizophrenia. Schizophr Bull 2011; 37: 451–455.
43. Bergink V, Gibney SM, Drexhage HA. Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 2014; 75: 324–331.
44. Gubert C, Stertz L, Pfaffenseller B, Panizzutti BS, Rezin GT, Massuda R et al. Mitochondrial activity and oxidative stress markers in peripheral blood mono-nuclear cells of patients with bipolar disorder, schizophrenia, and healthy sub-jects. J Psychiatr Res 2013; 47: 1396–1402.
45. Epel ES. Psychological and metabolic stress: a recipe for accelerated cellular aging? Hormones (Athens) 2009; 8: 7–22.
46. Kao HT, Cawthon RM, Delisi LE, Bertisch HC, Ji F, Gordon D et al. Rapid telomere erosion in schizophrenia. Mol Psychiatry 2008; 13: 118–119.
47. Cannon KE, Hudzik TJ. Suicide: Phenomenology and Neurobiology. Springer International Publishing: Cham, Switzerland, 2014.
48. Chen QH, Wang QB, Zhang B. Ethnicity modifies the association between functional microRNA polymorphisms and breast cancer risk: a HuGE meta-analysis. Tumour Biol 2014; 35: 529–543.